Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 11/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 8/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1786988 | 0.98 | PNMT (0.72) | PNMTADRA2AADRA2BADRA2C | |
| Nitric Acid SCHEMBL4718613 | 0.94 | PNMT (0.68) | PNMTADRA2AADRA2BADRA2C | |
| Nitric Acid SCHEMBL4718617 | 0.94 | PNMT (0.68) | PNMTADRA2AADRA2BADRA2C | |
| Trifluoroacetic Acid SCHEMBL384591 | 0.86 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1269277 | 0.85 | PNMT (0.87) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL29382023 | 0.85 | PNMT (1.00) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL324460 | 0.85 | PNMT (1.00) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL29651180 | 0.84 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL10004303 | 0.84 | PNMT (0.84) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL325622 | 0.84 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4558502-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-120051470-A | Azaquinazoline compounds and methods of use | 依安彼克医疗有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-12-26 | — | — | US | disclosed |
| EP-4441031-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| CN-118317949-A | Isoindolines as PMS2 inhibitors | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-114072398-B | Compounds that inhibit TDG activity | 上海仕谱生物科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-117486865-A | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-1562898-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-1554243-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
| US-20050085461-A1 | Benzenesulfonamide derivatives | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | US | disclosed |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1495004-A2 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 AND D2 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004046107-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004037788-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| WO-2003068732-A2 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 AND D2 RECEPTOR LIGA DS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| EP-1323710-A1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | Tanabe Seiyaku Co., Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085461-A1 | Benzenesulfonamide derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, SUCNR1 | PNMT 3338/4885ADRA2A 2877/4885ADRA2B 2469/4885 |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | FGF1, FGF2, FGFR1 | PNMT 4852/4885ADRA2A 2362/4885ADRA2B 2789/4885 |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | ALK, NPR1, SCO2 | PNMT 1740/4885ADRA2A 2277/4885ADRA2B 1700/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | PNMT 821/4885ADRA2A 628/4885ADRA2B 524/4885 |
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | PMS2, MSH2, RECQL | PNMT 1175/4885ADRA2A 968/4885ADRA2B 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.